Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy
详细信息    查看全文
文摘
class="listitem" id="list_ulist0010">
class="label">•

Efficacy of lapatinib might be predicted by hormone receptor expression.

class="label">•

Lapatinib benefits human epidermal growth factor receptor 2 (HER2)+hormone receptor (HR)– early breast cancer patients not receiving trastuzumab.

class="label">•

When trastuzumab is not offered lapatinib might be used in HER2+HR– breast cancer.

class="label">•

Numbers-needed-to-treat should be presented for patient subgroups of large studies.

© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号

地址:北京市海淀区学院路29号 邮编:100083

电话:办公室:(+86 10)66554848;文献借阅、咨询服务、科技查新:66554700